Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $173.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 83.85% year-over-year to $173.3 million; the TTM figure through Mar 2026 stood at $523.0 million (up 153.77% YoY), while the FY2025 annual figure was $181.2 million, up 83.78% from the prior year.
• Liabilities and Shareholders Equity eased to $173.3 million in Q1 2026 per IKT's latest filing, from $181.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $181.2 million in Q4 2025 and bottomed at $4.4 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $55.8 million across 5 years, with a median of $28.6 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 75.52% — and 2025, when it soared 1718.52%.
• Inhibikase Therapeutics' Liabilities and Shareholders Equity stood at $24.9 million in 2022, then sank by 41.83% to $14.5 million in 2023, then surged by 579.69% to $98.6 million in 2024, then jumped by 83.78% to $181.2 million in 2025, then fell by 4.34% to $173.3 million in 2026.
• Business Quant data shows IKT's Liabilities and Shareholders Equity at $173.3 million in Q1 2026, $181.2 million in Q4 2025, and $79.6 million in Q3 2025.